Srinath Sanda, MD

Title(s)Associate Professor, Pediatrics
SchoolSchool of Medicine
Address513 Parnassus Ave, MSB
San Francisco CA 94117
Phone415-514-5234
vCardDownload vCard

    Collapse Overview 
    Collapse Interests

    Collapse Research 
    Collapse Research Activities and Funding
    Functional Interrogation of Non-Coding Type 1 Diabetes Risk Variants in Human Immune Cells and Beta Cells
    NIH DP3DK111914Sep 30, 2016 - May 31, 2021
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. JCI Insight. 2021 Nov 08; 6(21). Greenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, Gitelman SE, Wilson DM, Gaglia JL, Griffin KJ, Russell WE, Raskin P, Moran A, Willi SM, Tsalikian E, DiMeglio LA, Herold KC, Moore WV, Goland R, Harris M, Craig ME, Schatz DA, Baidal DA, Rodriguez H, Utzschneider KM, Nel HJ, Soppe CL, Boyle KD, Cerosaletti K, Keyes-Elstein L, Long SA, Thomas R, McNamara JG, Buckner JH, Sanda S, ITN058AI EXTEND Study Team. PMID: 34747368.
      View in: PubMed   Mentions:
    2. Approaches to Establishing Tolerance in Immune Mediated Diseases. Front Immunol. 2021; 12:744804. Huffaker MF, Sanda S, Chandran S, Chung SA, St Clair EW, Nepom GT, Smilek DE. PMID: 34616405; PMCID: PMC8488342.
      View in: PubMed   Mentions:    Fields:    
    3. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021 08; 9(8):502-514. Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA, Gleevec Trial Study Group. PMID: 34214479; PMCID: PMC8494464.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    4. Diabetic ketoacidosis drives COVID-19 related hospitalizations in children with type 1 diabetes. J Diabetes. 2021 Aug; 13(8):681-687. Alonso GT, Ebekozien O, Gallagher MP, Rompicherla S, Lyons SK, Choudhary A, Majidi S, Pinnaro CT, Balachandar S, Gangat M, Curda Roberts AJ, Marks BE, Creo A, Sanchez J, Seeherunvong T, Jimenez-Vega J, Patel NS, Wood JR, Gabriel L, Sumpter KM, Wilkes M, Rapaport R, Cymbaluk A, Wong JC, Sanda S, Albanese-O'neill A. PMID: 33855813; PMCID: PMC8251108.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    5. Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy. J Allergy Clin Immunol. 2021 Oct; 148(4):1061-1071.e11. Shamji MH, Larson D, Eifan A, Scadding GW, Qin T, Lawson K, Sever ML, Macfarlane E, Layhadi JA, Würtzen PA, Parkin RV, Sanda S, Harris KM, Nepom GT, Togias A, Durham SR. PMID: 33819508.
      View in: PubMed   Mentions:    Fields:    
    6. Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers. J Clin Endocrinol Metab. 2021 03 25; 106(4):e1755-e1762. Ebekozien O, Agarwal S, Noor N, Albanese-O'Neill A, Wong JC, Seeherunvong T, Sanchez J, DeSalvo D, Lyons SK, Majidi S, Wood JR, Acharya R, Aleppo G, Sumpter KM, Cymbaluk A, Shah NA, Van Name M, Cruz-Aviles L, Alonso GT, Gallagher MP, Sanda S, Feuer AJ, Cossen K, Rioles N, Jones NY, Kamboj MK, Hirsch IB. PMID: 33410917; PMCID: PMC7928931.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    7. Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCR. PLoS One. 2020; 15(11):e0242049. Cortez FJ, Gebhart D, Robinson PV, Seftel D, Pourmandi N, Owyoung J, Bertozzi CR, Wilson DM, Maahs DM, Buckingham BA, Mills JR, Roforth MM, Pittock SJ, McKeon A, Page K, Wolf WA, Sanda S, Speake C, Greenbaum CJ, Tsai CT. PMID: 33186361; PMCID: PMC7665791.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsPHPublic Health
    8. Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen. J Allergy Clin Immunol. 2020 06; 145(6):1585-1597. Larson D, Patel P, Salapatek AM, Couroux P, Whitehouse D, Pina A, Johnson JL, Sever ML, Sanda S, Poyser J, Allio T, Scadding GW, Qin T, Shamji MH, Kwok WW, James EA, French D, Lelic A, Larché M, Altman MC, Togias A, Durham SR. PMID: 32169380.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    9. Effects of Combined Treatment with Cat Allergen Immunotherapy and Tezepelumab on Nasal Allergen Challenge. Journal of Allergy and Clinical Immunology. 2020 Feb 1; 145(2):ab336. Corren CJ, Wheatley WL, Sanda SS, Larson LD, Qin QT, Avila AP, Baroody BF, Greenberger GP, Hussain HI, Moss MM, Nelson NH, Saini SS, Tilles TS, Laurienzo LJ, Sever SM, Whitehouse WD, Yan YR, Nepom NG. .
      View in: Publisher Site   Mentions:
    10. Tolerance Development Following Oral Immunotherapy (OIT) in 1-3 Year Old Children with Peanut Allergy: Findings from the Immune Tolerance Network (ITN) IMPACT TRIAL. Journal of Allergy and Clinical Immunology. 2020 Feb 1; 145(2):ab338. Jones JS, Kim KE, Nadeau NK, Nowak-Wegrzyn NA, Wood WR, Sampson SH, Scurlock SA, Chinthrajan CS, Johnson JJ, Spain SK, Laurienzo LJ, Larson LD, Plaut PM, Qin QT, Sanda SS, Sever SM, Wheatley WL, Whitehouse WD, Yan YR, Burks BA. .
      View in: Publisher Site   Mentions:
    11. Survival in a bad neighborhood: pancreatic islets in cystic fibrosis. J Endocrinol. 2019 Feb 01. Norris AW, Ode KL, Merjaneh L, Sanda S, Yi Y, Sun X, Engelhardt JF, Hull RL. PMID: 30759072; PMCID: PMC6675675.
      View in: PubMed   Mentions: 7     Fields:    
    12. Hyaluronan levels are increased systemically in human type 2 but not type 1 diabetes independently of glycemic control. Matrix Biol. 2019 07; 80:46-58. Nagy N, Sunkari VG, Kaber G, Hasbun S, Lam DN, Speake C, Sanda S, McLaughlin TL, Wight TN, Long SR, Bollyky PL. PMID: 30196101; PMCID: PMC6401354.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    13. Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure. Diabetes Care. 2018 04; 41(4):823-830. Hull RL, Gibson RL, McNamara S, Deutsch GH, Fligner CL, Frevert CW, Ramsey BW, Sanda S. PMID: 29437698; PMCID: PMC5860832.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    14. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Cell Immunol. 2017 Sep; 319:3-9. Long SA, Thorpe J, Herold KC, Ehlers M, Sanda S, Lim N, Linsley PS, Nepom GT, Harris KM. PMID: 28844471; PMCID: PMC5614459.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    15. Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes. 2018 03; 19(2):271-276. Sanda S, Type 1 Diabetes TrialNet Study Group. PMID: 28707353; PMCID: PMC5849060.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Acute hyperglycemia impairs IL-6 expression in humans. Immun Inflamm Dis. 2016 Mar; 4(1):91-7. Spindler MP, Ho AM, Tridgell D, McCulloch-Olson M, Gersuk V, Ni C, Greenbaum C, Sanda S. PMID: 27042306; PMCID: PMC4768063.
      View in: PubMed   Mentions: 3     Fields:    
    17. Avidity-dependent programming of autoreactive T cells in T1D. PLoS One. 2014; 9(5):e98074. Durinovic-Belló I, Gersuk VH, Ni C, Wu R, Thorpe J, Jospe N, Sanda S, Greenbaum CJ, Nepom GT. PMID: 24844227; PMCID: PMC4028311.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    18. Use of a "fuzzy logic" controller in a closed-loop artificial pancreas. Diabetes Technol Ther. 2013 Aug; 15(8):628-33. Mauseth R, Hirsch IB, Bollyky J, Kircher R, Matheson D, Sanda S, Greenbaum C. PMID: 23829285.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    19. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013 Jun 01; 381(9881):1905-15. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Canakinumab Study Group, Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T, AIDA Study Group. PMID: 23562090; PMCID: PMC3827771.
      View in: PubMed   Mentions: 132     Fields:    Translation:HumansCells
    20. CD4+ T cells recognize diverse epitopes within GAD65: implications for repertoire development and diabetes monitoring. Immunology. 2013 Mar; 138(3):269-79. Yang J, James EA, Sanda S, Greenbaum C, Kwok WW. PMID: 23228173; PMCID: PMC3573280.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    21. Correlation of TSH with the risk of paediatric thyroid carcinoma. Clin Endocrinol (Oxf). 2012 Aug; 77(2):316-22. Chiu HK, Sanda S, Fechner PY, Pihoker C. PMID: 22404106.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    22. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes. 2012 Sep; 61(9):2340-8. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ, Diabetes TrialNet and the Immune Tolerance Network. PMID: 22721971; PMCID: PMC3425404.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    23. Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes. Diabetes. 2012 Jun; 61(6):1323-30. Greenbaum CJ, Schatz DA, Haller MJ, Sanda S. PMID: 22618767; PMCID: PMC3357268.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    24. A SNP in G6PC2 predicts insulin secretion in type 1 diabetes. Acta Diabetol. 2013 Jun; 50(3):459-62. Sanda S, Wei S, Rue T, Shilling H, Greenbaum C. PMID: 22438186.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    25. Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc Natl Acad Sci U S A. 2012 Mar 20; 109(12):E715-24. Kanter JE, Kramer F, Barnhart S, Averill MM, Vivekanandan-Giri A, Vickery T, Li LO, Becker L, Yuan W, Chait A, Braun KR, Potter-Perigo S, Sanda S, Wight TN, Pennathur S, Serhan CN, Heinecke JW, Coleman RA, Bornfeldt KE. PMID: 22308341; PMCID: PMC3311324.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansAnimalsCells
    26. Discovery of T cell antigens by high-throughput screening of synthetic minigene libraries. PLoS One. 2012; 7(1):e29949. Hondowicz BD, Schwedhelm KV, Kas A, Tasch MA, Rawlings C, Ramchurren N, McIntosh M, D'Amico LA, Sanda S, Standifer NE, Shendure J, Stone B. PMID: 22253836; PMCID: PMC3257230.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    27. Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J Immunol. 2012 Jan 01; 188(1):487-96. Habib T, Funk A, Rieck M, Brahmandam A, Dai X, Panigrahi AK, Luning Prak ET, Meyer-Bahlburg A, Sanda S, Greenbaum C, Rawlings DJ, Buckner JH. PMID: 22105996; PMCID: PMC3670766.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCellsCTClinical Trials
    28. Comment on: Atkinson. It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes 2011;60:361-363. Diabetes. 2011 Jun; 60(6):e17, author reply e18. Sanda S, Greenbaum CJ. PMID: 21617183; PMCID: PMC3114381.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes. Clin Immunol. 2010 Aug; 136(2):170-3. Sanda S, Bollyky J, Standifer N, Nepom G, Hamerman JA, Greenbaum C. PMID: 20483667.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    30. A T1D-associated Variant of PTPN2 Correlates with Decreased IL-2/IL-15 Responsiveness, Reduced FOXP3 Expression and Altered CD8 T Cell Differentiation. Clinical Immunology. 2010 Jan 1; 135:s118. Long LS, Cerosaletti CK, Shilling SH, Bollyky BP, Rawlings RD, Sanda SS, Buckner BJ. .
      View in: Publisher Site   Mentions:
    31. High-throughput Screening for CD8+ T Cell Epitopes Targeted in Type 1 Diabetes. Clinical Immunology. 2010 Jan 1; 135:s19. Hondowicz HB, Schwedhelm SK, Kas KA, Tasch TM, Ramchurren RN, Standifer SN, Sanda SS, Rawlings RC, Shendure SJ, Stone SB. .
      View in: Publisher Site   Mentions:
    32. Reduced CD11b Integrin Expression with Short-term Administration of an IL-1R Antagonist in Type 1 Diabetes Patients. Clinical Immunology. 2010 Jan 1; 135:s106-s107. Sanda SS, Bollyky BJ, Nepom NG, Hamerman HJ, Greenbaum GC. .
      View in: Publisher Site   Mentions:
    33. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes. 2010 Feb; 59(2):407-15. Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, Zhang ZY, Pihoker C, Sanda S, Greenbaum C, Buckner JH. PMID: 19875613; PMCID: PMC2809970.
      View in: PubMed   Mentions: 121     Fields:    Translation:HumansCells
    34. Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects. Eur J Immunol. 2009 Feb; 39(2):612-20. Long SA, Walker MR, Rieck M, James E, Kwok WW, Sanda S, Pihoker C, Greenbaum C, Nepom GT, Buckner JH. PMID: 19180473; PMCID: PMC2743096.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    35. T.128. Short-term Administration of Anakinra does not Appear to Affect Stimulated C-peptide Responses Acutely in Patients with Type 1 Diabetes. Clinical Immunology. 2009 Jan 1; 131:s89. Sanda SS, Bollyky BJ, Burwell BE, Standifer SN, Nepom NG, Greenbaum GC. .
      View in: Publisher Site   Mentions:
    36. F.69. Selection of Antigen Specific Autoreactive T Cells is Influenced by INS-VNTR Genotype. Clinical Immunology. 2009 Jan 1; 131:s112. Durinovic-Bello DI, Wu WR, Sanda SS, Nepom NG. .
      View in: Publisher Site   Mentions:
    37. OR.62. Impaired IL-2 Responsiveness and Treg Persistence in T1D is Revealed by Disease-Associated Variants in PTPN2. Clinical Immunology. 2009 Jan 1; 131:s26-s27. Long LS, Bollyky BP, Cerosaletti CK, Shilling SH, Pihoker PC, Sanda SS, Greenbaum GC, Buckner BJ. .
      View in: Publisher Site   Mentions:
    38. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol. 2008 Nov 15; 181(10):7350-5. Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH. PMID: 18981158; PMCID: PMC2597079.
      View in: PubMed   Mentions: 132     Fields:    Translation:HumansCells
    39. Type 1 diabetes mellitus: primary, secondary, and tertiary prevention. Mt Sinai J Med. 2008 Aug; 75(4):385-97. Bollyky J, Sanda S, Greenbaum CJ. PMID: 18729155.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    40. Autosomal dominant hypoparathyroidism with severe hypomagnesemia and hypocalcemia, successfully treated with recombinant PTH and continuous subcutaneous magnesium infusion. J Pediatr Endocrinol Metab. 2008 Apr; 21(4):385-91. Sanda S, Schlingmann KP, Newfield RS. PMID: 18556971.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    41. Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes. Clin Immunol. 2008 May; 127(2):138-43. Sanda S, Roep BO, von Herrath M. PMID: 18304876.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    42. A child with pericardial effusion and cardiac tamponade due to previously unrecognized hypothyroidism. J Natl Med Assoc. 2007 Dec; 99(12):1411-3. Sanda S, Newfield RS. PMID: 18229779; PMCID: PMC2575930.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    43. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol. 2007 Dec; 7(12):988-94. von Herrath M, Sanda S, Herold K. PMID: 17982429.
      View in: PubMed   Mentions: 110     Fields:    Translation:HumansAnimalsCells
    44. Reduced Foxp3 and Interleukin 10 Expression During the Partial Remission Phase of Type 1 Diabetes in Children. Clinical Immunology. 2007 Jan 1; 123:s16. Sanda SS, Roep RB, von Herrath vM. .
      View in: Publisher Site   Mentions: